Jiangxi Rimag Group's (HKG:2522) filing application regarding its H share full circulation of 51,562,074 unlisted shares has been accepted by China Securities Regulatory Commission (CSRC), a Friday bourse filing said.
The shares represent a little over 14% of the Chinese medical imaging company's total issued share capital.
The H-share circulation is still subject to regulatory approvals, including the filing notice of the CSRC, as well as the conversion and listing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments